Related papers: Optimized Treatment Schedules for Chronic Myeloid …
While many novel therapies have been approved in recent years for treating patients with multiple myeloma, there is still no established curative regimen, especially for patients with high risk disease. In this work, we use a mathematical…
The evolutionary dynamics of a system of cancerous cells in a model of chronic myeloid leukemia (CML) is investigated by a statistical approach. Cancer progression is explored by applying a Monte Carlo method to simulate the stochastic…
The long-term efficacy of targeted therapeutics for cancer treatment can be significantly limited by the type of therapy and development of drug resistance, inter alia. Experimental studies indicate that the factors enhancing acquisition of…
Chemotherapy is one of the primary modalities of cancer treatment. Chemotherapy drug administration is a complex problem that often requires expensive clinical trials to evaluate potential regimens. One way to alleviate this burden and…
We propose deterministic and stochastic models for studying the pharmacokinetics of chronic myeloid leukemia (CML), upon administration of IFN-$\alpha$ (the traditional treatment for CML), TKI (the current frontline medication for CML) and…
We present a three-stage probabilistic model for the progression of Chronic Myeloid Leukemia (CML), as manifested by the leukemic stem cells, progenitor cells and mature leukemic cells. This progression is captured through the process of…
Acute Myeloid Leukemia (AML) is one of the most aggressive types of hematological neoplasm. To support the specialists' decision about the appropriate therapy, patients with AML receive a prognostic of outcomes according to their…
Chronic Myeloid Leukemia (CML) is a biphasic malignant clonal disorder that progresses, first with a chronic phase, where the cells have enhanced proliferation only, and then to a blast phase, where the cells have the ability of…
While the use of combination therapy is increasing in prevalence for cancer treatment, it is often difficult to predict the exact interactions between different treatment forms, and their synergistic/antagonistic effects on patient health…
Malignant gliomas (MGs), particularly glioblastoma, are among the most aggressive brain tumors, with limited treatment options and a poor prognosis. Maximal safe resection and the so-called Stupp protocol are the standard first-line…
Although optimal control theory has been used for the theoretical study of anti-cancerous drugs scheduling optimization, with the aim of reducing the primary tumor volume, the effect on metastases is often ignored. Here, we use a previously…
Sequential monotherapy is the most widely used therapeutic approach in the treatment of HBV chronic infection. Unfortunately, under therapy, in some patients the hepatitis virus mutates and gives rise to variants which are drug resistant.…
The interactions between tumor cells and the immune system play a crucial role in cancer evolution. In this study, we explore how these interactions influence cancer progression by modeling the relationships among naive T cells, effector T…
A mathematical model for time development of metastases and their distribution in size and carrying capacity is presented. The model is used to theoretically investigate anti-cancer therapies such as surgery and chemical treatments…
Non-small cell lung cancer (NSCLC) is often intrinsically resistant to several first- and second-line therapeutics and can rapidly acquire further resistance after a patient begins receiving treatment. Treatment outcomes are therefore…
Randomized controlled trials estimate average treatment effects, but treatment response heterogeneity motivates personalized approaches. A critical question is whether statistically detectable heterogeneity translates into improved…
Immunotherapy is currently regarded as the most promising treatment to fight against cancer. This is particularly true in the treatment of chronic lymphocytic leukemia, an indolent neoplastic disease of B-lymphocytes which eventually causes…
We study the dynamics and interactions between combined chemotherapy and chimeric antigen receptor (CAR-T) cells therapy and malignant gliomas (MG). MG is one of the most common primary brain tumor, with high resistance to therapy and…
Cell heterogeneity plays an important role in patient responses to drug treatments. In many cancers, it is associated with poor treatment outcomes. Many modern drug combination therapies aim to exploit cell heterogeneity, but determining…
We present a new mathematical model of colorectal cancer growth and its response to monoclonal-antibody (mAb) therapy. Although promising, most mAb drugs are still in trial phases, and the possible variations in the dosing schedules of…